GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for vision loss: Long-Term study of pegcetacoplan for dry AMD
Disease control CompletedThis study tested the long-term safety and effectiveness of pegcetacoplan in 792 people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. Participants had previously been in earlier pegcetacoplan trials. The goal was to see …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental gene therapy aims to slow vision loss from dry AMD
Disease control CompletedThis study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The treatment is injected into the eye and aims to slow the growth of damaged areas. Researchers measured chan…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New syringe could make eye injections easier for macular degeneration patients
Disease control CompletedThis study tested a drug called pegcetacoplan, given as an eye injection using a prefilled syringe, in 44 people with geographic atrophy (a form of advanced age-related macular degeneration). The main goal was to see if the new syringe is safe and easy for doctors to use. The dru…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New eye drug shows promise in slowing blindness from dry AMD
Disease control CompletedThis study tested an eye injection called Zimura (avacincaptad pegol) in 448 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes permanent vision loss. The goal was to see if the drug could slow the growth of damaged areas in the retin…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: IVERIC bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Study reveals how eye damage tracks with vision decline in dry AMD
Knowledge-focused CompletedThis study examined how vision loss progresses in people with geographic atrophy, an advanced form of dry age-related macular degeneration. Researchers analyzed past medical records and eye images from 60 patients to see which retinal changes are linked to faster vision decline. …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: IRCCS Ospedale San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC